Response to: Zoledronate Increases Bone Mineral Density in Nonambulant Children With Cerebral Palsy: A Randomized, Controlled Trial

Anne Trinh^{1

2

3}, Frances Milat^{1

2

3}

Affiliations

¹ Department of Endocrinology, Monash Health, Melbourne 3168, Australia.
² Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Monash University, Melbourne 3168, Australia.
³ Department of Medicine, School of Clinical Sciences, Monash University, Melbourne 3168, Australia.

Editorial

Anne Trinh et al. J Clin Endocrinol Metab. 2023.

. 2023 Dec 21;109(1):e418-e419.

doi: 10.1210/clinem/dgad386.

Anne Trinh^{1

2

3}, Frances Milat^{1

2

3}

¹ Department of Endocrinology, Monash Health, Melbourne 3168, Australia.
² Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Monash University, Melbourne 3168, Australia.
³ Department of Medicine, School of Clinical Sciences, Monash University, Melbourne 3168, Australia.

No abstract available

Keywords: cerebral palsy; osteoporosis; pediatric; zoledronic acid.

Comment on

Zoledronate Increases Bone Mineral Density in Nonambulant Children With Cerebral Palsy: A Randomized Controlled Trial.
Granild-Jensen JB, Møller-Madsen B, Rackauskaite G, Farholt S, Søndergaard C, Sørensen TH, Vestergaard ET, Langdahl BL. Granild-Jensen JB, et al. J Clin Endocrinol Metab. 2023 Oct 18;108(11):2840-2851. doi: 10.1210/clinem/dgad299. J Clin Endocrinol Metab. 2023. PMID: 37235798 Clinical Trial.